Literature DB >> 9874449

Nuclear accumulation of p53 in colorectal adenocarcinoma: prognostic importance differs with race and location of the tumor.

U Manne1, H L Weiss, R B Myers, O K Danner, C Moron, S Srivastava, W E Grizzle.   

Abstract

BACKGROUND: Although several studies have been conducted to examine the role of p53 genetic abnormalities and their prognostic value in colorectal carcinoma, the incidence of nuclear accumulation of p53 and the prognostic importance of nuclear accumulation of p53 in African-American and white patients have not been investigated separately. Therefore, the authors evaluated the prognostic significance of p53 nuclear accumulation in these two racial groups.
METHODS: Nuclear accumulation of p53 was evaluated immunohistochemically in archival tissue specimens from 204 African-American and 300 white patients with primary colorectal adenocarcinomas who had undergone surgery. Survival times from colorectal adenocarcinoma were analyzed using Kaplan-Meier survival estimates and the Cox proportional hazards model for nuclear accumulation of p53 with adjustments for other confounding demographic and clinical variables.
RESULTS: Approximately equivalent proportions of distal (54%) and proximal adenocarcinomas (47%) were positive for nuclear accumulation of p53 in African-American patients. In contrast, distal colorectal adenocarcinomas from white patients more frequently were positive for nuclear accumulation of p53 than adenocarcinomas of the proximal colon (63% vs. 38%, respectively). Nuclear accumulation of p53 was found to be a strong predictor of poor survival in white patients (hazard ratio = 6.77; P = 0.0001) but not in African-American patients with primary adenocarcinomas of the proximal colon. Nuclear accumulation of p53 was not of prognostic value in patients of either race with primary adenocarcinomas of the distal colorectum.
CONCLUSIONS: Nuclear accumulation of p53 is a valuable indicator of poor prognosis only for white patients with adenocarcinomas of the proximal colon. The current study also suggests that the role of p53 dysregulation in colorectal adenocarcinomas may vary with the anatomic location of the tumor and the race of the patient. These findings suggest that the demographic characteristics of patients should be considered in the evaluation of prognostic markers of colorectal neoplasia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9874449     DOI: 10.1002/(sici)1097-0142(19981215)83:12<2456::aid-cncr8>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  21 in total

1.  Standards for immunohistochemical imaging: a protein reference device for biomarker quantitation.

Authors:  Donald H Atha; Upender Manne; William E Grizzle; Paul D Wagner; Sudhir Srivastava; Vytas Reipa
Journal:  J Histochem Cytochem       Date:  2010-08-30       Impact factor: 2.479

2.  Socioeconomic status, p53 abnormalities, and colorectal cancer.

Authors:  Emily Vogtmann; Chandrakumar Shanmugam; Venkat R Katkoori; John Waterbor; Upender Manne
Journal:  J Gastrointest Oncol       Date:  2013-03

3.  Bax expression is a candidate prognostic and predictive marker of colorectal cancer.

Authors:  Venkat R Katkoori; Catalina Suarez-Cuervo; Chandrakumar Shanmugam; Nirag C Jhala; Tom Callens; Ludwine Messiaen; James Posey; Harvey L Bumpers; Sreelatha Meleth; William E Grizzle; Upender Manne
Journal:  J Gastrointest Oncol       Date:  2010-12

4.  Molecular Biomarkers of Colorectal Cancer and Cancer Disparities: Current Status and Perspective.

Authors:  Upender Manne; Trafina Jadhav; Balananda-Dhurjati Kumar Putcha; Temesgen Samuel; Shivani Soni; Chandrakumar Shanmugam; Esther A Suswam
Journal:  Curr Colorectal Cancer Rep       Date:  2016-09-20

5.  Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer.

Authors:  David S Williams; Dmitri Mouradov; Clare Browne; Michelle Palmieri; Meg J Elliott; Rebecca Nightingale; Catherine G Fang; Rita Li; John M Mariadason; Ian Faragher; Ian T Jones; Leonid Churilov; Niall C Tebbutt; Peter Gibbs; Oliver M Sieber
Journal:  Mod Pathol       Date:  2019-08-30       Impact factor: 7.842

Review 6.  Colorectal Cancer Disparity in African Americans: Risk Factors and Carcinogenic Mechanisms.

Authors:  Gaius J Augustus; Nathan A Ellis
Journal:  Am J Pathol       Date:  2017-11-09       Impact factor: 4.307

7.  Recurrence and survival predictive value of phenotypic expression of Bcl-2 varies with tumor stage of colorectal adenocarcinoma.

Authors:  Chakrapani Chatla; Nirag C Jhala; Venkat R Katkoori; Dominik Alexander; Sreelatha Meleth; William E Grizzle; Upender Manne
Journal:  Cancer Biomark       Date:  2005       Impact factor: 4.388

8.  Tumor TP53 expression status, body mass index and prognosis in colorectal cancer.

Authors:  Teppei Morikawa; Aya Kuchiba; Xiaoyun Liao; Yu Imamura; Mai Yamauchi; Zhi Rong Qian; Reiko Nishihara; Kaori Sato; Jeffrey A Meyerhardt; Charles S Fuchs; Shuji Ogino
Journal:  Int J Cancer       Date:  2011-11-19       Impact factor: 7.396

9.  Translational pathology of neoplasia.

Authors:  William E Grizzle; Sudhir Srivastava; Upender Manne
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

10.  p53 Nuclear accumulation and Bcl-2 expression in contiguous adenomatous components of colorectal adenocarcinomas predict aggressive tumor behavior.

Authors:  Chandrakumar Shanmugam; Venkat R Katkoori; Nirag C Jhala; William E Grizzle; Gene P Siegal; Upender Manne
Journal:  J Histochem Cytochem       Date:  2007-12-10       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.